A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results

Andrew Zolopa; Paul E. Sax; Edwin Dejesus; Anthony Mills; Calvin Cohen; David Wohl; Joel E. Gallant; Hui C. Liu; Andrew Plummer; Kirsten L. White; Andrew K. Cheng; Martin S. Rhee; Javier Szwarcberg

doi:10.1097/QAI.0b013e318289545c

A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results

Andrew Zolopa, Paul E. Sax, Edwin Dejesus, Anthony Mills, Calvin Cohen, David Wohl, Joel E. Gallant, Hui C. Liu, Andrew Plummer, Kirsten L. White, Andrew K. Cheng, Martin S. Rhee, Javier Szwarcberg

School of Medicine

Research output: Contribution to journal › Article › peer-review

134 Scopus citations

Abstract

We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA

Original language	English (US)
Pages (from-to)	96-100
Number of pages	5
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	63
Issue number	1
DOIs	https://doi.org/10.1097/QAI.0b013e318289545c
State	Published - May 1 2013

Keywords

cobicistat
efficacy
HIV
phase 3 randomized trial
safety
stribild

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

Access to Document

10.1097/QAI.0b013e318289545c

Fingerprint

Dive into the research topics of 'A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results'. Together they form a unique fingerprint.

Cite this

Zolopa, A., Sax, P. E., Dejesus, E., Mills, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Plummer, A., White, K. L., Cheng, A. K., Rhee, M. S., & Szwarcberg, J. (2013). A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results. Journal of Acquired Immune Deficiency Syndromes, 63(1), 96-100. https://doi.org/10.1097/QAI.0b013e318289545c

A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results. / Zolopa, Andrew; Sax, Paul E.; Dejesus, Edwin et al.
In: Journal of Acquired Immune Deficiency Syndromes, Vol. 63, No. 1, 01.05.2013, p. 96-100.

Research output: Contribution to journal › Article › peer-review

Zolopa, A, Sax, PE, Dejesus, E, Mills, A, Cohen, C, Wohl, D, Gallant, JE, Liu, HC, Plummer, A, White, KL, Cheng, AK, Rhee, MS & Szwarcberg, J 2013, 'A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results', Journal of Acquired Immune Deficiency Syndromes, vol. 63, no. 1, pp. 96-100. https://doi.org/10.1097/QAI.0b013e318289545c

Zolopa A, Sax PE, Dejesus E, Mills A, Cohen C, Wohl D et al. A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results. Journal of Acquired Immune Deficiency Syndromes. 2013 May 1;63(1):96-100. doi: 10.1097/QAI.0b013e318289545c

Zolopa, Andrew ; Sax, Paul E. ; Dejesus, Edwin et al. / A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection : Analysis of week 96 results. In: Journal of Acquired Immune Deficiency Syndromes. 2013 ; Vol. 63, No. 1. pp. 96-100.

@article{3597c8cc4754446fb18339eaba58d458,

title = "A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results",

abstract = "We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA ",

keywords = "cobicistat, efficacy, HIV, phase 3 randomized trial, safety, stribild",

author = "Andrew Zolopa and Sax, {Paul E.} and Edwin Dejesus and Anthony Mills and Calvin Cohen and David Wohl and Gallant, {Joel E.} and Liu, {Hui C.} and Andrew Plummer and White, {Kirsten L.} and Cheng, {Andrew K.} and Rhee, {Martin S.} and Javier Szwarcberg",

year = "2013",

month = may,

day = "1",

doi = "10.1097/QAI.0b013e318289545c",

language = "English (US)",

volume = "63",

pages = "96--100",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection

T2 - Analysis of week 96 results

AU - Zolopa, Andrew

AU - Sax, Paul E.

AU - Dejesus, Edwin

AU - Mills, Anthony

AU - Cohen, Calvin

AU - Wohl, David

AU - Gallant, Joel E.

AU - Liu, Hui C.

AU - Plummer, Andrew

AU - White, Kirsten L.

AU - Cheng, Andrew K.

AU - Rhee, Martin S.

AU - Szwarcberg, Javier

PY - 2013/5/1

Y1 - 2013/5/1

N2 - We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA

AB - We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA

KW - cobicistat

KW - efficacy

KW - HIV

KW - phase 3 randomized trial

KW - safety

KW - stribild

UR - http://www.scopus.com/inward/record.url?scp=84876283495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876283495&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318289545c

DO - 10.1097/QAI.0b013e318289545c

M3 - Article

C2 - 23392460

AN - SCOPUS:84876283495

SN - 1525-4135

VL - 63

SP - 96

EP - 100

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 1

ER -

A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this